- Kazia Therapeutics (NASDAQ:KZIA) soars 22% after-hours after announcing new paxalisib data which will presented at SNO Annual Meeting, held virtually from 19-21 November 2020.
- New interim analysis of paxalisib phase II study in glioblastoma is highly consistent with prior data.
- Median progression-free survival (PFS) of 8.4 months vs. 5.3 months for temozolomide, the existing standard of care.
- Median overall survival (OS) of 17.5 months reported, vs. 12.7 months for temozolomide.
- Phase 1 study in DIPG shows paediatric maximum tolerated dose (MTD) of 27 mg/m2, with safety profile and pharmacokinetics similar to adult data.
- In terms of PFS, the proportion of patients alive and progression-free at six months was 96%, which compares favorably to an historical control of 58%.
- The company expects final data from both paxalisib phase II study and DIPG study in H1 2021.
- The paxalisib arm of the GBM AGILE study has moved into an operational phase, and first patient in is expected early in Q1 2021.
- Kazia will hold a conference call on November 18, 8pm ET to discuss the results further.
- https://seekingalpha.com/news/3637356-kazia-stockplus-22-on-positive-paxalisib-data-in-glioblastoma
Wednesday, November 18, 2020
Kazia jumps on positive paxalisib data in glioblastoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.